Emerging Markets Earnings Roundup: AstraZeneca (Part 12)
This article was originally published in PharmAsia News
Executive Summary
Who’s on first in China? That might be the a good question for AstraZeneca’s chief Pascal Soriot after the CEO of Pfizer also went out of his way to highlight second quarter success in the Middle Kingdom.
You may also be interested in...
AstraZeneca’s Brilinta Gives Brilliant Sales Performance
AstraZeneca’s cardiovascular drug Brilinta – one of the group’s five key growth platforms - seems to have turned the corner to give a stellar performance in the second quarter – particularly in the crucial US market.
San Francisco-based FibroGen Gets SFDA Nod Through Green Channel Procedure
HONG KONG - San Francisco-based FibroGen announced that Chinese regulators approved the start of clinical trials of novel therapy FG-4592 for anemia associated with chronic kidney disease. The approval was expedited through China's two-year-old special approval procedure, or "green channel.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.